Process for the manufacture of thyrocalcitonin

• US 4,041,022 A
• Filed: 08/15/1975
• Issued: 08/09/1977
• Est. Priority Date: 05/24/1967
• Status: Expired due to Term

• Current Assignee: Ciba-Geigy Corporation (Novartis Ag)
• Original Assignee: Ciba-Geigy Corporation (Novartis Ag)
• Inventors: Neher, Robert, Kahnt, Friedrich Werner
• Primary Examiner(s): Phillips, Delbert R.
• Application Number:
  US05/604,966
• Time in Patent Office: 725 Days
• Field of Search: 260/112.5 T
• US Class Current: 530/307
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: C07K 14/585 Calcitonins
• CPC Class Codes: Y10S 530/854 Glands

Abstract

Pure thyrocalcitonin (α and β) and process for its manufacture from thyroid gland tissue by extraction with a solvent system containing water and a lower alkanol at a pH of about 1-6.

Claims

1. Process for the procurement of porcine thyrocalcitonin which comprises extracting defatted porcine thyroid gland tissue at least once with a solvent system comprising essentially water and a lower alkanol at a pH of about 1-6, and precipitating thyrocalcitonin from the extract(s) at least once with trichloracetic acid and subjecting the thus-obtained crude thyrocalcitonin to counter-current distribution in a solvent system containing n-butanol and water and gel chromatography on polyacryl amide having a fractionation range from molecular weights of 1000 - 5000 or to counter-current dialysis to yield the pure (1) thyrocalcitonin, (2) thyrocalcitonin-sulfoxide or (3) mixture of thyrocalcitonin and thyrocalcitonin-sulfoxide.

2. Process according to claim 1, wherein the defatted thyroid gland tissue is pre-purified with 95% ethanol or 15% aqueous trichloracetic acid.

3. Process according to claim 1, wherein a solvent system is used which contains n-butanol as lower alkanol.

4. Process according to claim 1, wherein a solvent system is used which contains ethanol as lower alkanol.

5. Process according to claim 1, wherein a solvent system is used which contains glacial acetic acid.

6. Process according to claim 1, wherein a solvent system is used which contains formic acid.

7. Process according to claim 1, wherein a solvent system is used which contains an organic base, especially pyridine.

8. Process according to claim 1, wherein the resulting crude product is further purified by counter-current dialysis.